These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 22575316)

  • 1. Plasma PCSK9 levels and clinical outcomes in the TNT (Treating to New Targets) trial: a nested case-control study.
    Huijgen R; Boekholdt SM; Arsenault BJ; Bao W; Davaine JM; Tabet F; Petrides F; Rye KA; DeMicco DA; Barter PJ; Kastelein JJ; Lambert G
    J Am Coll Cardiol; 2012 May; 59(20):1778-84. PubMed ID: 22575316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkers.
    Arsenault BJ; Barter P; DeMicco DA; Bao W; Preston GM; LaRosa JC; Grundy SM; Deedwania P; Greten H; Wenger NK; Shepherd J; Waters DD; Kastelein JJ;
    J Am Coll Cardiol; 2011 Jan; 57(1):63-9. PubMed ID: 21185503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of PCSK9 polymorphisms on plasma lipids and response to atorvastatin treatment in Brazilian subjects.
    Anderson JM; Cerda A; Hirata MH; Rodrigues AC; Dorea EL; Bernik MM; Bertolami MC; Faludi AA; Hirata RD
    J Clin Lipidol; 2014; 8(3):256-64. PubMed ID: 24793346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients.
    Costet P; Hoffmann MM; Cariou B; Guyomarc'h Delasalle B; Konrad T; Winkler K
    Atherosclerosis; 2010 Sep; 212(1):246-51. PubMed ID: 20619837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study.
    Waters DD; LaRosa JC; Barter P; Fruchart JC; Gotto AM; Carter R; Breazna A; Kastelein JJ; Grundy SM
    J Am Coll Cardiol; 2006 Nov; 48(9):1793-9. PubMed ID: 17084252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term impact of low-dose atorvastatin on serum proprotein convertase subtilisin/kexin type 9.
    Guo YL; Liu J; Xu RX; Zhu CG; Wu NQ; Jiang LX; Li JJ
    Clin Drug Investig; 2013 Dec; 33(12):877-83. PubMed ID: 24114461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.
    Schwartz GG; Bessac L; Berdan LG; Bhatt DL; Bittner V; Diaz R; Goodman SG; Hanotin C; Harrington RA; Jukema JW; Mahaffey KW; Moryusef A; Pordy R; Roe MT; Rorick T; Sasiela WJ; Shirodaria C; Szarek M; Tamby JF; Tricoci P; White H; Zeiher A; Steg PG
    Am Heart J; 2014 Nov; 168(5):682-9. PubMed ID: 25440796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term effects of ezetimibe-plus-statin therapy on low-density lipoprotein cholesterol levels as compared with double-dose statin therapy in patients with coronary artery disease.
    Okada K; Iwahashi N; Endo T; Himeno H; Fukui K; Kobayashi S; Shimizu M; Iwasawa Y; Morita Y; Wada A; Shigemasa T; Mochida Y; Shimizu T; Sawada R; Uchino K; Umemura S; Kimura K
    Atherosclerosis; 2012 Oct; 224(2):454-6. PubMed ID: 22892323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trial.
    Byun YS; Lee JH; Arsenault BJ; Yang X; Bao W; DeMicco D; Laskey R; Witztum JL; Tsimikas S;
    J Am Coll Cardiol; 2015 Apr; 65(13):1286-1295. PubMed ID: 25835440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9.
    Careskey HE; Davis RA; Alborn WE; Troutt JS; Cao G; Konrad RJ
    J Lipid Res; 2008 Feb; 49(2):394-8. PubMed ID: 18033751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia.
    Roth EM; McKenney JM; Hanotin C; Asset G; Stein EA
    N Engl J Med; 2012 Nov; 367(20):1891-900. PubMed ID: 23113833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma proprotein convertase subtilisin kexin type 9 is a heritable trait of familial combined hyperlipidaemia.
    Brouwers MC; van Greevenbroek MM; Troutt JS; Bonner Freeman A; Lu A; Schaper NC; Konrad RJ; Stehouwer CD
    Clin Sci (Lond); 2011 Nov; 121(9):397-403. PubMed ID: 21539517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans.
    Persson L; Cao G; Ståhle L; Sjöberg BG; Troutt JS; Konrad RJ; Gälman C; Wallén H; Eriksson M; Hafström I; Lind S; Dahlin M; Amark P; Angelin B; Rudling M
    Arterioscler Thromb Vasc Biol; 2010 Dec; 30(12):2666-72. PubMed ID: 20884874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of niacin, statin, and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 levels in patients with dyslipidemia.
    Khera AV; Qamar A; Reilly MP; Dunbar RL; Rader DJ
    Am J Cardiol; 2015 Jan; 115(2):178-82. PubMed ID: 25432415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of effects of pitavastatin versus pravastatin on serum proprotein convertase subtilisin/kexin type 9 levels in statin-naive patients with coronary artery disease.
    Nozue T; Hattori H; Ishihara M; Iwasaki T; Hirano T; Kawashiri MA; Yamagishi M; Michishita I
    Am J Cardiol; 2013 May; 111(10):1415-9. PubMed ID: 23433768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined administration of RG7652, a recombinant human monoclonal antibody against PCSK9, and atorvastatin does not result in reduction of immune function.
    Gelzleichter TR; Halpern W; Erwin R; Baruch A; Leabman M; Forrest AS; Satterwhite CM; Peng K; Chilton J; Stevens D
    Toxicol Sci; 2014 Aug; 140(2):470-80. PubMed ID: 24848798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the Treating to New Targets (TNT) cohort.
    Thompson JF; Hyde CL; Wood LS; Paciga SA; Hinds DA; Cox DR; Hovingh GK; Kastelein JJ
    Circ Cardiovasc Genet; 2009 Apr; 2(2):173-81. PubMed ID: 20031582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Predicts Future Risk of Cardiovascular Events Independently of Established Risk Factors.
    Leander K; Mälarstig A; Van't Hooft FM; Hyde C; Hellénius ML; Troutt JS; Konrad RJ; Öhrvik J; Hamsten A; de Faire U
    Circulation; 2016 Mar; 133(13):1230-9. PubMed ID: 26896437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol.
    Welder G; Zineh I; Pacanowski MA; Troutt JS; Cao G; Konrad RJ
    J Lipid Res; 2010 Sep; 51(9):2714-21. PubMed ID: 20525997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma proprotein convertase subtilisin kexin type 9 levels are related to markers of cholesterol synthesis in familial combined hyperlipidemia.
    Brouwers MC; Konrad RJ; van Himbergen TM; Isaacs A; Otokozawa S; Troutt JS; Schaefer EJ; van Greevenbroek MM; Stalenhoef AF; de Graaf J
    Nutr Metab Cardiovasc Dis; 2013 Nov; 23(11):1115-21. PubMed ID: 23333725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.